FTSE 100 giant GSK eyes more than £40bn in sales by 2031 February 5, 2025 Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth quarter earnings. The London-listed pharma giant reported core earnings per share of 23.2p for the quarter, a drop of around 20 per cent year-on-year. However, this was greater than the 19p that analysts [...]
Support for innovation is needed in Budget warns pharmaceutical industry October 15, 2024 The Association of the British Pharmaceutical Industry (ABPI) has called on Rachel Reeves to prioritise research and development (R&D) investment in the coming Labour Budget to unlock the potential of the UK life sciences sector. The APBI’s pre-Budget submission stressed the importance of maintaining and increasing public R&D funding to increase the UK’s attractiveness as [...]
Meet the founder searching for the ‘holy grail’ of cancer treatment October 8, 2024 Jennifer Sieg speaks with Hilmar Warenius about how his discovery of a new type of cancer treatment could be well on its way to revolutionising the pharmaceutical industry
Astrazeneca drags down the FTSE 100 following mixed cancer trial results September 10, 2024 Shares in Astrazenca and Daiichi Sankyo nose dived today after the pair revealed mixed results in their lung cancer drug's late-stage trial.
GSK receives US breakthrough therapy designation for lung cancer treatment August 20, 2024 Pharmaceutical group GSK has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) for a key lung cancer treatment. The breakthrough therapy designation is designed to expedite the development and review of drugs with the potential to treat a serious condition. Only treatments that are shown to offer a substantial improvement [...]
Hikma given shot in the arm by ‘excellent’ double-digit growth August 8, 2024 Pharmaceutical firm Hikma has hiked its dividend and raised its guidance having hailed an “excellent” first half of the year. The Jordanian-founded FTSE 100 pharma firm, which in June bolstered its injectables offering with the purchase of Danish rival Xellia, posted a double-digit revenue rise of 10 per cent, raking in $1.6bn (£1.3bn) in the [...]
GSK: Pharma giant raises guidance after second quarter sales give shot in the arm July 31, 2024 London-listed pharma giant GSK has raised its guidance after a strong second quarter beat market expectations, boosted by its cancer and HIV portfolio. Total sales in the second quarter of 2024 reached £7.9bn, an increase of 13 per cent year on year. Core operating profit at the pharma company rose by 18 per cent on [...]
Indivior shares plunge after US move and profit warning July 9, 2024 Indivior lowered its annual adjusted operating profit forecast and shares in the company plunged.
GSK to pay Curevac £1.2bn for full rights to develop and commercialise mRNA vaccines July 3, 2024 GSK will assume full control of developing and manufacturing the candidate vaccines and will have worldwide rights to commercialise them.
Astrazeneca drug gets US approval for use on endometrial cancer June 17, 2024 Astrazeneca's Imfinzi drug has gained FDA approval for use on patients with primary or advanced endometrial cancer.